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ABSTRACT 
 
In the US, the incidence and mortality rates of prostate cancer (PCa) are higher among 
African American men compared to European American men. Obesity is an important risk factor 
of PCa. Obesity is known to alter the gene expression profiles in prostate tumors. This study 
evaluates the impact of obesity and the expression of obesity-related genes on the progression of 
PCa in African American men.  
The primary outcome of interest is biochemical recurrence (BCR) of  PCa. There were 
48 African American prostate cancer patients in the study. The tissue samples included 42 
normal tissues, 40 Prostate Intraepithelial Neoplasia (PIN) and 45 tumor tissues (127 tissue 
samples in total). We assembled 99 obesity-related genes and determined the levels of their 
expression in the three types of tissue samples using Nanostring Technologies.  An ANOVA test 
was used to compare the means for gene expression among normal, PIN and tumor tissue 
samples. Unconditional logistic regression models were used to calculate odds ratios (ORs) and 
their respective 95% confidence intervals (95% CIs) to determine the association between 
obesity and BCR as well as gene expression and BCR. Results were regarded as statistically 
significant if p-values were less than 0.05. A Kaplan Meier Curve was constructed to depict the 
survival time and time to event (BCR) among obese and non-obese African American prostate 
cancer patients. Patients were followed up from the date of first surgery to the date of 
biochemical recurrence or date of last follow-up. Statistical analysis was done with SAS 9.4 
software. 
 v 
 
  Forty-three obesity-related genes were statistically significantly associated with 
biochemical recurrence. There was no association between obesity and biochemical recurrence 
(BCR) in obese African American men compared to non-obese African American men (OR= 
2.03, 95% CI = 0.22 - 18.77, p-value= 0.53). Twenty genes showed an upward trend in gene 
expression among normal, PIN and tumor tissue samples including ADIPOR1, AKRIC4, 
ALOX12, ALOX15, CRYBB2, EIF5A, ERG, GNPDA2, HNF1B, HSD3B1, KLK4, LEP, MC4R, 
MTCH2, PCSK1, PIK3CB, SLC2A2, STAT1, SULT1A1, YY1. The probability of survival (not 
having BCR) is lower in obese African American men compared to non-obese African American 
men as indicted in the Kaplan Meier curve. In other words, the probability of developing BCR is 
higher in obese African American men compared to non-obese African American men. 
We did not find a significant association between obesity and biochemical recurrence. 
However, we elucidated some obesity-related genes that could explain PCa carcinogenesis. 
Further studies are needed to determine functional significance of these selected obesity-related 
genes and the role they play in encouraging PCa progression in African American men. 
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INTRODUCTION 
Health Disparities in Prostate Cancer  
There is an apparent disparity in prostate cancer (PCa) among different races in the 
United States (US). African American men (AAM) are disproportionately affected by the burden 
of prostate cancer. Amongst European American men, the incidence rate of prostate cancer is 
approximately 113 per 100,000 persons while the prostate cancer incidence rate is approximately 
189 per 100,000 persons in African American males (National Cancer Institute, 2017b). In terms 
of prostate cancer death rates, approximately 19 per 100,000 White men die from prostate cancer 
while 42 per 100, 000 AAM die from prostate cancer (National Cancer Institute, 2017b). Hence, 
African American males have both the highest incidence rate and mortality rate of prostate 
cancer compared to other races in the US. There are risk factors that are likely responsible for 
these disparities. The socio-economic status (SES) of an individual is a potential risk factor for 
prostate cancer disparity.  A study by (Byers et al., 2008) showed that low SES significantly 
elevated the risk of dying from prostate cancer among men. The risk was elevated because of 
later diagnosis of prostate cancer and less aggressive treatment. Being a minority population in 
the US, AAM are more likely to have a low SES.  Low SES compromises the health of 
individuals. These individuals tend to lack access to health care and health insurance coverage 
(Becker & Newsom, 2003, American Cancer Society, 2016, Fiscella & Williams, 2004). In terms 
of median value of assets, Whites have a net worth of $103976 while Blacks have a net worth of 
$9211 (US Census Bureau, 2017). Low SES encourages behavioral risk factors that increase the 
risk of prostate cancer development. 
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   Behavioral risk factors for prostate cancer disparities including lack of access to healthy 
foods, obesity, physical inactivity, cigarette smoking, alcohol consumption and other health 
behaviors are more common among people with low SES and minority population (Pampel, 
Krueger, & Denney, 2010). In terms of diet and prostate cancer risk, consumption of red meat, 
high fat diets and low carotenoid intake increases the risk of prostate cancer (Jianjun, Dhakal, 
Greene, Lang, & Kadlubar, 2011). A study by Taksler, Keating, & Cutler (2012) that was aimed 
at elucidating the differences in prostate cancer attributed to race revealed that the estimated 
disparity in prostate cancer mortality was 1320 more cases per 100000 males amongst Black 
males compared with White males. This disparity was due to an increased number of new cases 
of prostate cancer among Black males (76%) as well as an increased stage-specific death rate at 
diagnosis (24%).  Twenty-nine percent of the difference in the number of new cases of metastatic 
prostate cancer between Black men compared to White men was attributed to the variation in 
income, pre-existing health conditions and prostate specific antigen (PSA) testing while the 
characteristics of tumor at diagnosis explained fifty percent in racial differences of prostate 
cancer (Taksler et al., 2012).  
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Obesity and Prostate Cancer Risk 
Obesity, which is a chronic health condition is a risk factor for other chronic diseases 
including high blood pressure, stroke and different types of cancer like breast and prostate cancer 
(American Cancer Society, 2016). Epidemiological evidence revealed that obesity is associated 
with poorer treatment outcomes and higher risk of mortality due to prostate cancer 
(Buschemeyer & Freedland, 2007). Obese men are more likely to experience prostate cancer 
recurrence after treatment than non-obese men. A study by (Freedland et al., 2004) revealed that  
obesity rate is 31% in African American men compared to 21% in White men. They also showed 
that obesity is linked with higher grade tumors.  In the US, the prevalence of obesity is greater in 
Black men than in Whites men. The obesity prevalence is 38% in Black men compared to 35% 
in White men (American Cancer Society, 2016). Physical activity reduces the risk of cancer 
remission but the prevalence of no leisure physical activity is 34% in Black men compared to 
25% in White men (American Cancer Society, 2016). Among men treated with radical 
prostatectomy, obese patients were more likely to have more pronounced biochemical failure 
rates (Freedland et al., 2004). Obesity also modifies the levels of certain hormones that are 
related to prostate cancer risk such as testosterone, leptin, insulin-like-growth-factor-1 and 
estrogen (Buschemeyer & Freedland, 2007, Freedland & Aronson, 2004). 
The association between obesity and aggressive prostate cancer as a health outcome can 
be explained through different mechanisms of action. These mechanisms may be more 
pronounced in an obese patient, who has general hormone changes that leads to increased 
estradiol, lower sex hormone binding protein and low free testosterone, which results in an 
aggressive form of prostate cancer (Freedland & Aronson, 2004). Another mechanism in obese 
males is insulin resistance leading to high insulin levels, which results in an aggressive form of 
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prostate cancer (Buschemeyer & Freedland, 2007). Adiponectin, a protein hormone found in 
adipose tissues is responsible for the regulation of fatty acids and glucose in the body and plays a 
crucial role in obesity-related cancers including cancer of the prostate (Kelesidis, Kelesidis, & 
Mantzoros, 2006, Rider et al., 2015, RJ & English, 2006). A low level of adiponectin in the body 
suggests risk for the progression and aggressiveness of prostate cancer (Obeid & Hebbard, 
2012).  
Overview of Genetic Variation and Prostate Cancer Risk 
Variation occurs whenever the order of the bases in a DNA sequence changes. Variations 
can involve only one base or many bases (National Institute of Health, 2017). If the two strands 
of a chromosome are thought of as nucleotides threaded on a string, then, for example, a string 
can break and the order of the bases can vary. One or more nucleotides may be changed, added, 
or removed. In chromosomes, these changes are called Single Nucleotide Polymorphisms 
(SNPS) (National Institute of Health, 2017), insertions, and deletions (Mullaney, Mills, Stephen 
Pittard, & Devine, 2010). 
In addition to these changes, some DNA sequences called “repeats” like to insert extra 
copies of themselves several times. Chromosomes can also undergo more dramatic changes 
called translocations (Nambiar & Raghavan, 2011). These occur when an entire section of DNA 
on one chromosome switches places with a section on another. The risk for prostate cancer can 
be exacerbated in the presence of a variation in the gene of an individual. This variation could be 
brought about by some mechanisms such as gene mutations, miRNA alterations, genetic 
polymorphisms and epigenetic modification (Arun et al., 2017). 
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Gene Mutation  
An inheritance of a mutated gene poses a risk for prostate cancer as well as the 
aggressiveness of the disease. Family history of prostate cancer is important in determining the 
risk of prostate cancer (American Cancer Society, 2017). Mutation in genes such as BRCA1, 
BRCA2, HOXB13 (National Cancer Institute, 2017c) are good predictors of prostate cancer risk. 
A study conducted by (Pritchard et al., 2016) found that men with metastatic prostate cancer 
were more likely to have an inherited mutation in the gene responsible for DNA-repair compared 
with men diagnosed with a localized prostate cancer. They identified mutations in 16 genes 
including BRCA2, ATM, CHEK2, BRCA1, PALB2 and RAD51D. The number of new cases of 
mutations in DNA repair genes was approximately 12% in men with metastatic prostate cancer, 
which exceeded the number of DNA repair gene mutation in men with localized prostate cancer 
(Pritchard et al., 2016).  DNA-repair genes are responsible for the maintenance of genes, 
prevention and correction of errors during DNA replication (Cancer Information and Support 
Network, 2017). 
Genetic Polymorphisms 
Single Nucleotide Polymorphisms (SNP) is a type of genetic variation in which there is a 
change in the arrangement of nucleotides in a DNA (National Institute of Health, 2017). A study 
carried out by Lipson et al., (2014) was aimed at determining whether the GWAS replication 
SNPs and candidate SNPs that showed evidence for prostate cancer susceptibility can also 
indicate prostate cancer aggressiveness. They found that among the 34 GWAS replicated SNPs, 
4 were associated with prostate cancer aggressiveness in African American males. These SNPs 
were rs2660753, rs13254738, rs10090154, rs2735839. Two of the SNPs were found on 8q24 
while the other two SNPs were found on 3p12 and 19q13.  Jianjun et al., (2011) evaluated 
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whether there was an association between the polymorphism in hOGG1 and XRCC1 genes and 
risk of prostate cancer. They found a positive association and the effect of the genes were 
modified by plasma antioxidants. These genes are involved in the repair of oxidative DNA 
damage. Thus, an existence of variation in these genes increases the risk of prostate cancer.   
Genetic variation in the HNF1B is associated with prostate cancer risk (Chornokur et al., 2013), 
although the underlying mechanistic pathway(s) remain elusive.  Obese men with rs7501939 C-
allele were found to have a higher risk of prostate cancer. rs7501939 is located in the HNF1B 
gene that regulates proliferation of prostate cancer (Ross-Adams et al., 2015). Furthermore, 4 of 
the 12 single nucleotide polymorphisms (rs10993994, rs5945619, rs4430796, and rs9364554) 
studied by Grisanzio et al., (2012) showed a strong association with five genes: MSMB, NCOA4, 
NUDT11, HNF1B, and SLC22A3. These genes were involved in prostate cancer pathogenesis.  
Gene Expression and Prostate Cancer Risk 
Ideally, DNA are the building blocks of genes. Genes produce functional end-products 
such as proteins through the process of gene-expression (National Cancer Institute, 2018). For 
every gene, individuals have different levels of proteins. Enzymes are proteins and different 
people have variation of the same enzyme. The process of gene expression starts with a DNA, 
which undergoes transcription to form an RNA. The RNA is then translated into a protein 
(National Cancer Institute, 2018). In other words, the presence or absence of a functional enzyme 
depends on whether an individual expresses the gene responsible for the enzyme as well as the 
level at which the gene is expressed. Consequently, expression levels of certain enzymes likely 
have an association with prostate cancer risk (Donkena & Young, 2011, Nghiem et al., 2016). 
Proteins may also come in the form of hormones. Androgen metabolism genetics and prostate 
cancer risk has been well established. Higher levels of androgen increases the risk of prostate 
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cancer (Michaud, Billups, & Partin, 2015). African American males usually have higher levels of 
androgen compared to other races (C. M. Zeigler-Johnson et al., 2008). Although impact of 
testosterones on the risk of prostate cancer is still inconclusive, testosterone metabolites, such as 
dihydotestosterone (DHL)  increase the risk of prostate cancer (Gann, Hennekens, Ma, 
Longcope, & Stampfer, 1996). Variations in certain enzymes such as CYP3A4, CYP3A43 and 
CYP3A5 which are responsible for the activation of testosterone hormone, are associated with the 
aggressiveness of prostate cancer both in African American males and European American males 
(C. Zeigler-Johnson et al., 2004). Park et al., (2006) found that there was an association between 
the deletion polymorphism of an enzyme called UDP-Glucuronosyltransferase 2B17 and an 
increased risk of prostate cancer among AAM and Caucasian men. The enzyme is responsible 
for the glucuronidation of many chemicals as well as androgen. In other words, UDP-
Glucuronosyltransferase 2B17 facilitates the excretion of these chemicals and hormones.  
Preliminary studies have evaluated the association of gene expression and the risk of 
prostate cancer progression. Nghiem et al., (2016) analyzed the association between the 
expression of mismatch repair enzymes and prostate cancer risk. They found no association 
between the mismatch repair enzymes and biochemical recurrence. Powell et al.,( 2013) showed 
that genes associated with prostate cancer are expressed differently between European American 
males and African American males. Singh et al., (2002) demonstrated that the expression of 
genes can predict the behavioral outcome of prostate cancer in patients. Chandran et al., (2007) 
delineated the potential genes expressed in prostate cancer patients that influence the progression 
of the disease. In a study conducted by Yu et al., (2004), there was evidence of a difference in 
the genes expressed in the tumor and non-tumor samples. They also found that the expression of 
these genes might serve as a prognosticative factor in determining the aggressiveness of prostate 
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cancer. Mortensen et al., (2015) discovered the expression of twelve genes that were predictors 
of biochemical recurrence of prostate cancer. They also found that patients with recurrence had 
an up-regulated expression of SFRP gene.  
 Significance of the Study 
Obesity is known to alter the gene expression profiles in prostate tumors (Ornish et al., 
2008, Ribeiro et al., 2012). Hence, it is imperative to understand the role of obesity in prostate 
cancer risk in order to inform adequate control of prostate cancer. There is evidence that tumors 
derived from African American men are more aggressive in nature compared to tumors from 
European American men (Castro et al., 2009, Lipson et al., 2014, Timofeeva et al., 2009, 
Zeigler-Johnson et al., 2004). It is possible that obesity would influence prostate carcinogenesis 
in African- American males (AAM), although the studies aimed to verify this hypothesis are 
lacking. 
Our study hypothesis is that obesity may be associated with an increased risk for prostate 
cancer progression in obese African American men compared to non-obese African American 
men. We selected a novel candidate-driven selective approach over the traditional non-candidate 
gene expression profiling. We tested this hypothesis by: 
a. Comparing the means for gene expression among tumor tissue, Prostatic Intraepithelial 
Neoplasia (PIN) and normal tissue. 
b. Testing the trend of gene expression among tumor, PIN and normal tissues. 
c. Comparing the means for gene expression among tumor tissue, Prostatic Intraepithelial 
Neoplasia (PIN) and normal tissue stratified by obese and non-obese patients. 
d. Testing the association between obesity and the biochemical recurrence of prostate 
cancer after initial surgery with the use of a multiple logistic regression 
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e. Testing the association between gene expression and biochemical recurrence of prostate 
cancer using logistic regression models at a 95% confidence interval. 
f. Constructing a Kaplan Meier Curve depicting the time to event (biochemical recurrence) 
among obese and non-obese African American prostate cancer patients. 
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METHODOLOGY 
Tissue Processing and Sample Selection 
We obtained tissue samples from 48 African American prostate cancer patients Total 
Cancer Care bank (a biological specimen repository at Moffitt). The tissue samples included 42 
normal tissues, 40 Prostate intraepithelial Neoplasia (PIN) and 45 Tumor tissues. There was a 
total of 127 tissue samples in our study. The samples are formalin fixed paraffin embedded 
(FFPE). These samples are linked to the epidemiological, clinical and follow up data. Our 
primary outcome is the biochemical recurrence of prostate cancer (BCR). Patients’ demographic 
and clinical data were obtained, including, age, height, weight, BMI, Gleason score (including 
primary and secondary Gleason scores), Prostate Specific Antigen (PSA), Cancer of the Prostate 
Risk Assessment (CAPRA) Score, seminal vesicle invasion, surgical margins, lymph node 
invasion and extra capsular extension. Patients were followed up from the date of first surgery to 
the date of biochemical recurrence or date of last follow-up. A Moffitt pathologist identified and 
marked tumor, PIN and normal regions. RNA samples were extracted from marked tissues for 
gene expression profiling. 
Expression Assay 
 We used the nCounter gene expression assays by NanoString technologies (Nanostring 
Technologies, 2017). These innovative assays can analyze the formalin fixed, paraffin embedded 
(FFPE) blocks, as well as fresh-frozen (FF) tumor tissues with comparable accuracy. The nCounter 
gene expression assays can analyze up to 800 genes in a single reaction using 100ng or less of total 
RNA or FFPE extract. These assays were provided at the Moffitt Center genomics core. 
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Gene Selection 
We assembled a list of “obesity-related” genes. A total of 99 obesity-related genes were 
included in the gene expression profiling. The databases including “Gene” by NCBI (National 
Center for Biotechnology Information, 2017), GeneCards (GeneCards, 2017) and Cancer 
Genome Anatomy Project (National Cancer Institute, 2017a) were used to ensure comprehensive 
search.  
Statistical Analysis 
We recoded and categorized the BMI scores in order to identify patients who were 
overweight and obese in the sample. The obese and overweight group were those with BMI ≥ 25 
while the non-obese and non-overweight group had BMI < 25. We decided to use a cut point of 
25 for BMI because overweight and obesity are likely related to an increased risk of prostate cancer 
recurrence after treatment (American Cancer Society, 2018). We also recoded and categorized the 
Gleason scores in order to determine the number of patients and their respective tissue samples 
with an aggressive Gleason score. Gleason scores determines the likelihood of prostate cancer 
spreading to other normal tissues (Stark et al., 2009). Gleason score ≥ 7 were recoded as aggressive 
while Gleason scores less than 7 were coded as non-aggressive Gleason scores. 
Descriptive statistics were used to summarize the participants’ demographic and clinical 
characteristics. Mean, standard deviation, minimum, maximum and range were calculated for 
continuous variables whereas frequency and percentage were generated for categorical variables. 
Gene expressions was normalized using internal housekeeping reference genes, and summarized 
using descriptive statistics.  We also summarized the descriptive statistics of the expression of 99 
genes for the three types of tissue sample using the mean, standard deviation and range. To 
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compare the means for gene expression among tumor tissue, prostatic intraepithelial neoplasia 
(PIN) and normal tissue, we used F test. Genes less than the alpha level of 0.05 were regarded as 
being differently expressed among the three types of tissue samples and statistically significant.  
We constructed a logistic regression model to test the association between obesity and the 
biochemical recurrence of prostate cancer after initial surgery. In order to control for 
confounding, we carried out a stepwise selection procedure for all covariates including  age, 
height, weight, BMI, Gleason score, Prostate Specific Antigen (PSA), Cancer of the Prostate 
Risk Assessment (CAPRA) Score, seminal vesicle invasion, surgical margins, lymph node 
invasion and extra capsular extension. The result of the stepwise selection determined the 
significant covariates that would be adjusted for in the logistic regression. No covariate met the 
significance level of entry (0.15) and significant level of stay (0.15) in the stepwise selection 
model. Hence, we did not adjust for any covariate in the final logistic model. 
  To determine the association between biochemical recurrence and gene expression, we 
first carried out a simple logistic regression for each of the 99 genes present in the study. We 
went further to generate a multiple logistic regression in order to control the presence of 
confounder. A stepwise selection procedure was done for the 99 genes individually. Variables 
such as age, height, weight, BMI, Gleason score, Prostate Specific Antigen (PSA), Cancer of the 
Prostate Risk Assessment (CAPRA) Score, seminal vesicle invasion, surgical margins, lymph 
node invasion and extra capsular extension were included in the stepwise selection procedure. 
The result of each stepwise selection procedure determined the significant covariates adjusted for 
each gene in the logistic regression. P-values ≤ 0.05 were regarded as statistically significant. 
The odds-ratio and 95% confidence interval for the association between gene expression and 
biochemical recurrence were recorded for the results with p-values ≤ 0.05. 
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We constructed a Kaplan Meier’s Curve to determine the time to event, in this case, 
prostate cancer recurrence among obese and non-obese African American prostate cancer 
patients. Data analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, 
USA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
 
 
 
 
 
RESULTS 
 
Table 1 shows a summary of the demographic and clinical characteristics of the prostate 
cancer patients in our sample. The statistics were stratified into the three types of tissues that we 
obtained, namely, normal tissue, prostatic intraepithelial neoplasia (PIN) and tumor tissue. 
Patients with normal tissue and PIN had a mean age of 54 years while patients with tumor tissue 
had a mean age of 55 years. The minimum and maximum heights of the patients were 161.50cm 
and 188cm respectively, while they had a minimum and maximum weights of 62.46kg and 
119.67kg respectively. The maximum BMI in our sample was 39.42 kg/m2.The average BMI for 
normal and tumor tissues was 29.08 kg/m2 while it was 28.90 kg/m2 in prostatic intraepithelial 
neoplasia. The prostate specific antigen (PSA) had a mean above 7ng/ml and a maximum value 
of 33.10ng/ml in the sample. This is as expected since all the patients in our sample already had 
prostate cancer. PSA levels ≤ 4ng/ml is regarded as normal, levels above 4ng/ml but less than 
10ng/ml could pose a threat while levels >10ng/ml significantly increase the risk of prostate 
cancer (American Cancer Society, 2017).  On a scale of 0-12, the Capra score had a maximum 
value of 11 for both normal and tumor tissues but a score of 9 for PIN. Capra score predicts the 
likelihood of prostate cancer progression after initial prostatectomy (Punnen et al., 2014). The 
average Gleason score for normal tissue, PIN and tumor tissue were 6.64, 6.58 and 6.62 
respectively. Normal and tumor tissues had a maximum Gleason score of 9 while PIN had a 
maximum value of 9. 
Table 2 shows the dichotomous clinical and demographic characteristics of the patients. 
Ten patients had a biochemical recurrence while thirty-eight patients did not have a biochemical 
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recurrence. Eighty-three percent (83%) of the patients were obese while 16.67% were non-obese. 
Aggressive Gleason score was evident in twenty-nine patients. In terms of metastasis of prostate 
cancer, two patients had a seminal vesicle invasion, twelve patients had surgical margins, one 
patient had a lymph node invasion while 14.58% of the patients had an extracellular extension. 
Table 3 shows the result of the F test used to compare the means of gene expression 
among the three types of tissue samples. Only expressed genes that were statistically 
significantly different among the three tissue samples are presented. A total of 29 genes were 
significantly expressed differently in the normal tissue, PIN and tumor tissue. 
Table 4 shows the result of the F test used to compare the means of gene expression 
among normal, PIN and tumor tissues stratified by obese and non-obese patients.  Genes that 
were statistically significantly different among obese and non-obese are marked with asterisk. A 
total of 6 genes out of the 29 obesity-related genes that showed a difference in the means for 
gene expression among tumor tissue, Prostatic Intraepithelial Neoplasia (PIN) and normal tissue, 
were significantly expressed differently between the obese and non-obese African American 
prostate cancer patients. 
Table 5 shows the result of the test of association between obesity and recurrence of 
prostate cancer after initial surgery.  We found no association between obesity and biochemical 
recurrence of prostate cancer in African American obese patients compared to African American 
non-obese patients (OR= 2.032,  95% CI = 0.220- 18.765, p-value= 0.5318). There is no 
association between obesity and biochemical recurrence because the p-value is above the alpha 
level of 0.05. 
Table 6 illustrates the result of the test of association between gene expression and 
biochemical recurrence of prostate cancer with no adjustment of covariates. A total of 35 genes 
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showed a statistically significant association with biochemical recurrence of prostate cancer with 
a p-value less than 0.05. Their respective odds ratios and 95% confidence intervals are also 
represented. 
Table 7 illustrates the result of the test of association between gene expression and 
biochemical recurrence of prostate cancer with the adjustment of potential covariates.  The 
covariates we adjusted for include age, height, weight, BMI, Gleason score, Prostate Specific 
Antigen (PSA), Cancer of the Prostate Risk Assessment (CAPRA) Score, seminal vesicle 
invasion, surgical margins, lymph node invasion and extra capsular extension. A total of 43 
genes out of the 99 obesity-related genes showed a statistically significant association with 
biochemical recurrence of prostate cancer with a p-value less than 0.05. Their respective odds 
ratios and 95% confidence intervals are also represented. 
In the Kaplan Meier curves illustrated in Figures 1, the probability of having no 
biochemical recurrence of prostate cancer at day zero is 100% or 1 for both the obese and non-
obese African American (AA) patients. However, over time the probability reduces such that at 
time 1000days, approximately 15% of obese patients have a biochemical recurrence (BCR) of 
prostate cancer while 0% of non-obese patients have BCR. In other words, the probability that an 
obese patient will not have a biochemical recurrence of prostate cancer (BCR) beyond the 1000th 
day of follow up is approximately 85% while the probability that a non-obese patient will not 
have BCR beyond the 1000th day is 100%. At 2000th day of follow up, the probability that an 
obese patient will not have BCR is 70% while the probability of not experiencing BCR is 
approximately 80% in non-obese AA prostate cancer patients. The probability that an obese 
patient will not have BCR beyond 3000days of follow-up is 62% in the obese AA patients 
compared to approximately 80% in the non-obese AA patients. The comparison between the two 
 17 
 
survival curves for obese and no-obese was not statistically significant as indicated by the (p-
value = 0.3118). 
Figure 2 shows the trend analysis of gene expression in normal, prostatic intraepithelial 
neoplasia and tumor tissue samples. Twenty genes showed an upward trend in gene expression 
including ADIPOR1, AKRIC4, ALOX12, ALOX15, CRYBB2, EIF5A, ERG, GNPDA2, HNF1B, 
HSD3B1, KLK4, LEP, MC4R, MTCH2, PCSK1, PIK3CB, SLC2A2, STAT1, SULT1A1, YY1. 
Table 8 shows the list of genes that showed an overlap between the result from the  trend 
test for gene expression among the three tissue samples and the result from the means 
comparison of gene expression that were significantly different between obese and non-obese 
patients among normal, PIN and tumor tissues. 
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Table 1: Descriptive and Clinical Characteristics for the 48 African American Prostate 
Cancer Patients 
                     Normal    
                          
Variable Mean Standard 
Deviation 
Minimum  Maximum   Range  
Age 54.29 7.20 40 72 32  
Height 177.17 6.31 161.50 188.00 26.50  
Weight 91.66 14.29 62.46 119.67 57.21  
PSA 7.50 5.77 1.30 33.10 31.80  
Capra 
Score 
2.38 2.46 0 11 11  
BMI 29.08 4.80 19.97 39.42 19.45  
Gleason 
Score 
6.64 0.62 6 9 3  
       
   PIN    
                          
Variable Mean Standard 
Deviation 
Minimum  Maximum   Range  
Age 54.03 6.90 40 66 26  
Height 177.41 6.13 161.50 188.00 26.50  
Weight 90.78 14.81 62.46 118.01 55.55  
PSA 7.26 5.72 1.40 33.10 31.70  
Capra 
Score 
2.15 2.17 0 9.0 9.0  
BMI 28.90 4.93 19.97 39.42 19.45  
Gleason 
Score 
6.58 0.50 6 7 1  
       
          
Tumor 
   
                          
Variable Mean Standard 
Deviation 
Minimum  Maximum   Range  
Age 54.51 6.66 40 70 32  
Height 176.81 6.10 161.50 188.00 26.50  
Weight 90.75 14.41 62.46 119.67 57.21  
PSA 7.13 5.63 1.30 33.10 31.80  
Capra 
Score 
2.04 2.40 0 11.00 11.00  
BMI 29.08 4.80 19.97 39.42 19.45  
Gleason 
Score 
6.62 0.61 6 9 3  
       
 
 19 
 
Table 2: Dichotomous Clinical and Demographic Characteristics for the 48 African 
American Prostate Cancer Patients 
  
Variable Frequency (%) 
  
Biochemical Recurrence  
Yes 10 (20.83) 
No 38 (79.17) 
  
Obesity  
High BMI 40 (83.33) 
Low BMI   8 (16.67) 
  
Aggressive Gleason Score  
Yes 29 (60.42) 
No 19 (39.58) 
  
Seminal Vesicle Invasion  
Yes    2 (4.17) 
No 46 (95.83) 
  
Surgical Margins  
Yes 12 (25) 
No 36 (75) 
  
Lymph Node Invasion  
Yes   1 (2.08) 
No 47 (97.92 
  
Extracellular Extension  
Yes   7 (14.58) 
No 41 (85.42) 
  
 
 
 
 
 
 
 
 
 
 
 
 20 
 
Table 3: Comparing the means for gene expression among Tumor Tissue, Prostatic 
Intraepithelial Neoplasia (PIN) and Normal Tissue. 
Gene         Normal 
Mean ± SD 
     PIN 
Mean ± SD 
   Tumor 
Mean ± SD 
Pr > F 
ADIPOR1 8.67 ± 0.33 8.84±0.31 8.85±0.35 0.00238 
AKRIC4 0.96 ± 0.84 1.18±1.01 1.78±1.34 0.0021 
ALOX12  1.91±1.12 2.27±1.06 2.51±1.16 0.0475 
ALOX15 2.01±0.85 2.84±0.95 3.24±1.15 <.0001 
ANGPT1 7.95±0.60 7.59±0.61 7.36±0.78 0.0004 
CRYBB2 2.56±0.91 2.75±0.87 3.11±1.09 0.0282 
EIF5A 10.67±0.20 10.81±0.31 10.90±0.30 0.0012 
ERG 4.62±0.69 4.90±1.20 5.29±1.53 0.0366 
FADS1 7.08±0.71 7.01±0.75 6.69±0.83 0.0488 
GNPDA2 6.75±0.34 6.82±0.32 6.98±0.50 0.0255 
HNF1B 5.27±0.66 5.64±0.59 5.74±0.78 0.0053 
HSD3B1 10.70±0.56 1.46±1.21 2.15±1.57 0.0127 
HSPB8 10.70±0.56 5.64±0.59 10.24±0.89 0.0115 
IL6 7.46±1.73 6.99±1.60 6.57±1.56 0.0441 
INSR 8.97±0.26 9.12±0.27 9.03±0.24 0.0464 
KLK4 11.26±0.80 11.55±0.65 11.77±0.83 0.0101 
LEP 0.96±0.80 1.48±0.93 1.86±1.09 0.0002 
MC4R 5.05±1.48 1.39±1.24 1.75±1.29 0.0427 
MTCH2 8.66±0.24 8.76±0.34 8.83±0.30 0.0206 
PCSK1 1.53±0.97 1.89±0.99 2.30±1.29 0.0063 
PIK3CB 6.57±0.39 6.72±0.32 6.79±0.47 0.0355 
PSCA 7.19±1.73 7.69±2.34 6.54±1.69 0.0305 
SLC2A2 0.85±0.93 1.04±1.04 1.64±1.40 0.0048 
SRD5A2 8.27±0.51 7.99±0.61 7.92±0.71 0.0248 
STAT1 9.57±0.33 9.77±0.41 9.85±0.47 0.0066 
SULT1A1 6.55±0.62 6.70±0.61 6.95±0.70 0.0168 
TFF1 4.48±1.04 4.92±1.35 4.15±1.01 0.0127 
TIMP3 11.41±0.48 10.97±0.48 10.83±0.55 <.0001 
YY1 8.72±0.22 8.85±0.28 8.86±0.23 0.0108 
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Table 4: Comparing the Means for Gene Expression among the Tissue types stratified by 
Obesity (Obese and Non-obese)  
Gene     Normal 
 
PIN Tumor 
 Obese by Non-obese Obese by Non-obese Obese by Non-obese 
      Pr > F Pr > F Pr > F 
ADIPOR1 0.7443 0.2154 0.5617 
AKRIC4 0.4752 0.2755 0.7141 
ALOX12 0.1407 0.3353 0.9110 
ALOX15 0.5497 0.6929 0.3508 
ANGPT1 0.6079 0.8102 0.3083 
CRYBB2 0.4120 0.9135 0.2009 
EIF5A 0.1239 0.6994 0.0329* 
ERG 0.4665 0.7902 0.6115 
FADS1 0.8594 0.4347 0.7493 
GNPDA2 0.9875 0.3207 0.1825 
HNF1B 0.7697 0.8566 0.07710 
HSD3B1 0.9710 0.5307 0.9136 
HSPB8 0.7937 0.7953 0.6937 
IL6 0.5406 0.5112 0.0242* 
INSR 0.4926 0.5637 0.8049 
KLK4 0.9703 0.9860 0.0527 
LEP 0.7613 0.5702 0.3050 
MC4R 0.5935 0.0362* 0.9865 
MTCH2 0.2883 0.9962 0.0479* 
PCSK1 0.7244 0.5192 0.8320 
PIK3CB 0.4733 0.1993 0.3659 
PSCA 0.5922 0.3288 0.4886 
SLC2A2 0.9801 0.7198 0.6501 
SRD5A2 0.5081 0.6497 0.8810 
STAT1 0.3280 0.4771 0.0894 
SULT1A1 0.0894 0.8403 0.0227* 
TFF1 0.8745 0.2061 0.1437 
TIMP3 0.8546 0.3463 0.0057* 
YY1 0.3644 0.4651 0.6183 
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Table 5: Testing the association between obesity and the recurrence of prostate cancer 
after initial surgery with the use of a multiple logistic regression 
Analysis of Maximum Likelihood Estimates 
Parameter DF Estimates Standard 
Error 
Wald 
Chi-Square 
Pr>ChiSq 
Intercept 1 -1.9459 1.0690 3.3132 0.0687 
BMI-Group 1 0.7091 1.1341 0.3910 0.5318 
Odds Ratio Estimates 
Effect Point Estimate 95% Wald  
Confidence Limits 
BMI-Group 2.032 0.220 18.765 
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Table 6: Simple Logistic Regression Testing the association between gene expression and 
biochemical recurrence of prostate cancer 
Gene       Pr > ChiSq OR 95% Confidence Interval 
ADIPOR1 0.0253 0.233 0.065 0.835 
AKT1 <0.0001 12.633 3.669 43.498 
ALOX12 0.0055 1.754 1.180 2.609 
ALOXI5B 0.0227 1.504 1.059 2.137 
APOLD1 <.0001 11.561 4.290 31.157 
AR 0.0053 0.214 0.073 0.632 
BMP2 0.0053 2.372 1.293 4.351 
EIF2A 0.0001 0.138 0.049 0.383 
EIF5A 0.0153 0.122 0.022 0.667 
FADS1 <.0001 4.354 2.126 8.919 
FOXO3 0.0188 5.806 1.339 25.178 
GPER1 0.0046 2.438 1.316 4.518 
HSPB8 0.0016 3.072 1.529 6.175 
INS 0.0175 1.617 1.088 2.404 
INSR 0.0109 9.271 1.670 51.460 
ITGBS 0.0071 0.134 0.031 0.579 
LEP 0.0434 1.532 1.013 2.317 
LEGALS8 <.0001 0.032 0.007 0.152 
MAPK1 <.0001 0.029 0.006 0.136 
NFKB1 0.0010 0.214 0.086 0.534 
NPC1 0.0372 0.145 0.024 0.892 
NPYIR 0.0272 1.922 1.076 3.434 
OR2LI3 0.0007 2.189 1.389 3.451 
PAH 0.0008 1.809 1.278 2.559 
RAB6A 0.0170 0.093 0.013 0.654 
RHOA 0.0059 6.710 1.730 26.027 
SHBG 0.0387 1.612 1.025 2.534 
SIRT1 0.0034 0.101 0.022 0.467 
SLC39A2 0.0244 1.380 1.043 1.827 
STAT1 0.0183 0.258 0.084 0.795 
STAT3 0.0002 15.674 3.758 65.365 
TFF1 0.0141 1.605 1.100 2.342 
TGFB1 0.0238 2.988 1.157 7.718 
TP53 <.0001 0.077 0.023 0.252 
YY1 0.0011 0.043 0.007 0.287 
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Table 7: Multiple Logistic Regression Testing the association between gene expression and 
biochemical recurrence of prostate cancer 
Gene       Pr > ChiSq OR 95% Confidence Interval 
ADIPOR1 0.0094 0.134 0.030 0.611 
ADIPOR2 0.0450 0.294 0.089 0.973 
AKT1 <.0001 30.802 6.500 145.963 
ALOX12 0.0089 1.815 1.161 2.838 
APOLD1 <.0001 12.807 4.597 35.685 
AR 0.0136 0.260 0.089 0.758 
BMP2 0.0035 2.908 1.422 5.947 
CXCR4 0.0320 1.814 1.053 3.126 
CYLD 0.0082 1.081 1.001 1.168 
EIF2A 0.0001 0.132 0.046 0.375 
EIF5A 0.0100 0.061 0.007 0.513 
ESR2 0.0456 1.742 1.011 3.000 
FADS1 0.0001 6.206 2.466 15.615 
FOXO3 0.0167 7.479 1.439 38.881 
GPER1 0.0047 2.918 1.388 6.132 
HSPB8 0.0009 3.857 1.739 8.553 
IGFBP3 0.0088 2.207 1.221 3.988 
INS 0.0215 1.725 1.084 2.747 
INSR 0.0119 14.381 1.800 114.915 
ITGB5 0.0046 0.121 0.028 0.522 
LGALS8 <.0001 0.036 0.008 0.172 
MAPK1 <.0001 0.009 0.001 0.068 
MMP9 0.0275 0.667 0.465 0.956 
NFKB1 0.0009 0.185 0.068 0.504 
NPC1 0.0116 0.062 0.007 0.538 
NPYIR 0.0024 3.127 1.496 6.534 
OR2LI3 0.0007 2.339 1.427 3.832 
PAH 0.0007 1.858 1.300 2.654 
PIK3C3 0.0303 5.950 1.185 29.864 
PIK3CB 0.0256 0.264 0.082 0.850 
PIK3RI 0.0469 3.340 1.017 10.973 
PLA2G2A 0.0388 0.705 0.506 0.982 
RAB6A 0.0320 0.116 0.016 0.830 
RHOA 0.0015 17.569 2.995 103.049 
SIRT1 0.0016 0.068 0.013 0.363 
SLC39A2 0.0048 1.585 1.151 2.183 
STAT1 0.0068 0.161 0.043 0.604 
STAT3 <.0001 126.617 14.071 >999.999 
TCF7L2 0.0312 9.453 1.225 72.931 
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Table 7: Multiple Logistic Regression Testing the association between gene expression and 
biochemical recurrence of prostate cancer (continued) 
 
TFF1 0.0170 1.685 1.098 2.587 
TGFB1 0.0126 4.007 1.347 11.914 
TP53 <.0001 0.061 0.017 0.220 
YY1 0.0006 0.030 0.004 0.222 
 
 
Table 8: An overlap of Genes 
 
 
 
 
 
 
 
 
 
 
Table 9: P-value for a Kaplan Meier Curve depicting the role of obesity in prostate cancer 
progression. 
Test of Equality over Strata 
Test Chi-Square DF Pr > Chi-Square 
Log-Rank 1.0230 1 0.3118 
Wilcoxon 0.7888 1 0.3745 
-2Log(LR) 1.5797 1 0.2088 
 
 
Gene 
EIF5A 
MC4R 
MTCH2 
SULT1A1 
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Figure 1: Kaplan Meier Curve depicting the role of obesity in prostate cancer progression. 
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Figure 2: Trend of Gene Expression in Normal, PIN and Tumor Tissue Sample 
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Figure 2: Trend of Gene Expression in Normal, PIN and Tumor Tissue Sample (continued) 
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Figure 2: Trend of Gene Expression in Normal, PIN and Tumor Tissue Sample (continued) 
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Figure 2: Trend of Gene Expression in Normal, PIN and Tumor Tissue Sample (continued) 
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Figure 2: Trend of Gene Expression in Normal, PIN and Tumor Tissue Sample (continued) 
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DISCUSSION 
 
Our study examined the association between obesity and biochemical recurrence of 
prostate cancer as well as the association between the RNA expression of obesity-related genes 
and biochemical recurrence of prostate cancer among African American men.  The analysis 
between obesity and biochemical recurrence (Table 5) showed no association between obesity 
and biochemical recurrence of prostate cancer in obese African American men (AAM) compared 
to non-obese African American men. Reasons for this lack of association could be due to low 
statistical power and small sample size in our study.  The Kaplan Meier Curve (Figure 1) depicts 
the survival time and time to event (biochemical recurrence) among obese and non-obese 
African American prostate cancer patients. The probability of survival (not having BCR) is lower 
in obese African American men compared to non-obese African American men. In other words, 
the probability of having biochemical recurrence is higher in obese African American men 
compared to non-obese African American men. 
In terms of the association between gene expression and biochemical recurrence of 
prostate cancer, we found forty-three obesity-related genes that were associated with biochemical 
recurrence after adjusting for potential confounders (Table 7). The confounders adjusted for in 
the multivariate models varied for each individual gene. The typical adjusted confounders were 
age at diagnosis, height, prostate specific antigen (PSA), Gleason score, surgical margins, 
CAPRAS score and extracapsular extension. The results (Table 7) suggests the importance of 
these genes in the progression of prostate cancer. Our findings is consistent with the study by 
(Wallace et al., 2008) which found that genes CXCR4 and MMP9 were highly expressed 
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metastasis-associated genes in African American men. Taichman et al., (2002) showed the 
mechanism of prostate cancer invasion of bones through the SDF-1/CXCR4 pathway. Literature 
supports the role of BMP2 in prostate cancer metastasis  (Jin, Dayyani, & Gallick, 2011, Powell 
et al., 2013). TP53 was responsible for prostate cancer recurrence in a study by (Ecke et al., 
2010), which is similar to our result. 
The analysis comparing the means of gene expression among normal, prostate 
intraepithelial neoplasia (PIN) and tumor tissues generated twenty-nine obesity-related genes that 
were differentially expressed out of the ninety-nine obesity-related genes (Table 3). We further 
stratified each tissue sample by obesity status. Out of the twenty-nine obesity-related genes, 
EIF5A, IL6, MC4R, MTCH2, SULT1A1 and TIMP3 were expressed differently among normal, 
PIN and tumor tissue samples (Table 4). IL6 which is called interleukin-6 causes inflammation 
and prostate cancer metastasis as discussed by (Nguyen, Li, & Tewari, 2014). 
A trend test comparing the means of gene expression among the three tissue samples 
(Figure 2) generated twenty obesity-related genes that showed a positive (upward) trend of the 
expression of genes and progression of the disease from normal tissue to prostate intraepithelial 
neoplasia to tumor tissue. This shows a potential biological plausibility of the expression of the 
genes in relation to the progression of the prostate cancer.  Flajollet et al., (2011) showed how 
ERG increases the expression of Osteopontin, a protein that is highly implicated in prostate 
cancer metastasis. Our finding showed an expression of ERG in a manner that explains prostate 
cancer progression. 
We determined the presence of an overlap between EIF5A, IL6, MC4R, MTCH2, 
SULT1A1, TIMP3 and the twenty obesity-related genes that showed a trend in gene expression. 
We found that four genes: EIF5A, MC4R, MTCH2, SULT1A1 showed an overlap (Table 8). 
 34 
 
EIF5A has been isolated as a cancer biomarker because of its overexpression and cancer 
proliferation function (Acta, 2016). Studies have shown the association between SULT1A1 and 
prostate cancer risk (Arslan, Silig, & Pinarbasi, 2011, Nowell et al., 2004). 
Limitations 
Sample size is a major limitation in our study. We had only 48 African American prostate 
cancer patients. Hence, we were unable to determine the true association between obesity and 
biochemical recurrence of prostate cancer due to a low statistical power. Larger sample size in 
future analysis is required in order to give a better estimate of this association. Additionally, we 
had nine obese patients with biochemical recurrence and only one non-obese patient with 
biochemical failure rate in our study. This suggests evidence of biased results since the size of 
the high risk subgroup (biochemical recurrence) is much larger for the exposed group (obese) 
than for the unexposed group (non-obese). Sample size is also the main reason why we had a cut 
point of  25 for BMI although overweight and obese individuals are likely to experience prostate 
cancer remission after treatment (American Cancer Society, 2018) 
In determining the presence of within subject correlation in our sample, we analyzed the 
43 obesity-related genes that were significant in the multiple logistic model testing the 
association between gene expression and biochemical recurrence. A spearman rho correlation 
test was conducted on the 43 obesity-related genes with BMI as a continuous variable. Only gene 
TCF7L2 showed a moderate negative correlation with BMI (-0.336, p-value = 0.0196). Hence, a 
linear relationship exists between gene TCF7L2 and BMI. 
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CONCLUSION 
 
In summary, we found no association between obesity and biochemical recurrence among 
obese African American men compared to non-obese African American men. We also elucidated 
obesity-related genes, which may play a role in biochemical recurrence of prostate cancer. 
Further analysis is vital to determine the functional significance of the selected genes in prostate 
carcinogenesis. 
Although we found no association between obesity and biochemical recurrence in our 
study, a study investigating the effect of obesity on biochemical control showed that obese 
patients were more likely to have a more pronounced biochemical failure rates (Freedland et al., 
2004). This simply suggests that more research on this subject is needed to determine the true 
impact of obesity on biochemical recurrence. Obesity is a chronic disease and it is a risk factor 
for other chronic diseases including heart disease and cancer. Hence, it was imperative to 
understand the role of obesity in prostate cancer risk in order to inform adequate control of 
prostate cancer. According to the American Cancer Society, (2016), physical activity reduces 
cancer recurrence and mortality in general. Obesity can impact the gene expression profiles in 
African American prostate cancer patients and influences their prostate cancer biochemical 
recurrence as shown in our study. Gene expression predicts the behavioral outcome of prostate 
cancer in patients (Singh et al., 2002) . Studies have shown that gene expression explains the 
progression and aggressiveness of prostate cancer (Chandran et al., 2007, Mortensen et al., 2015, 
Yu et al., 2004) . With the use of the selected genes from our study, genotyping and other 
molecular research methods can further explain the functional role of these obesity-related genes 
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in prostate cancer proliferation. Our research findings can be used to develop hypothesis for 
individualized prostate cancer risk estimation in African American men. Our research findings 
can also be used in the future to select the most appropriate treatment modalities and to estimate 
the risk of prostate cancer progression. 
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Appendix A: Descriptive Statistics for the Gene Expression of 99 Obesity-Related Genes 
among the Three Tissue Samples 
                                             
 
                     
 
   Type           Variable             Label                        Mean                         Std Dev                               Range 
         
    Normal       ACTN2                 ACTN2                     4.63                            2.82                                 11.12 
                         ADIPOQ              ADIPOQ                   1.36                            1.05                                  4.13 
                         ADIPOR1            ADIPOR1                  8.67                            0.33                                  1.37 
                         ADIPOR2            ADIPOR2                  6.51                            0.49                                   2.89 
                         AKR1C4              AKR1C4                     0.96                            0.84                                  2.87 
                         ALOX12              ALOX12                     1.91                            1.12                                  4.76 
                         ALOX15              ALOX15                     2.01                            0.85                                  3.24 
                         ALOX15B            ALOX15B                  8.80                            1.48                                  6.47 
                         ANGPT1              ANGPT1                   7.95                             0.60                                 2.05 
                         APOLD1              APOLD1                    7.49                            0.70                                 3.08 
                         AR                        AR                              8.67                            0.40                                 1.87 
                         BMP2                  BMP2                        5.09                            0.74                                 3.20 
                         CGA                     CGA                           2.01                             0.94                                 3.48 
                         CRYBB2               CRYBB2                    2.56                             0.91                                 4.02 
                         CSNK2A1            CSNK2A1                  7.99                             0.27                                 1.35 
                         CXCR4                 CXCR4                        8.97                            0.97                                 4.50 
                         CYLD                    CYLD                          7.06                            0.33                                 1.48 
                         CYP17A1             CYP17A1                   2.36                            1.09                                 4.25 
                         CYP19A1             CYP19A1                   2.01                            0.98                                 3.76 
                         CYP3A4               CYP3A4                      1.85                            0.99                                 3.64 
                         EIF2A                   EIF2A                         7.34                             0.44                                 1.82 
                         EIF5A                   EIF5A                         10.67                          0.20                                  0.86 
                         EPHB2                 EPHB2                        5.14                            0.64                                 2.50 
                         ERG                      ERG                            4.62                            0.68                                 3.73 
                         ESR1                    ESR1                           6.92                            0.80                                 3.53 
                         ESR2                    ESR2                           4.62                            0.81                                 2.71 
                         FADS1                 FADS1                        7.07                             0.70                                2.78 
                         FASN                   FASN                          10.13                           0.79                                3.26 
                         FOXO3                FOXO3                        8.98                            0.27                                1.21 
                         FTO                      FTO                             8.41                            0.29                                1.17 
                         GNPDA2             GNPDA2                     6.74                            0.33                                1.64 
                         GOLIM4              GOLIM4                      8.32                            0.30                                1.68 
                         GPER1                 GPER1                        5.56                             0.72                                3.03 
                         HLA_DRB3         HLA-DRB3                 10.30                            0.83                               3.79 
                         HNF1A                HNF1A                        1.96                             1.01                                4.03 
                         HNF1B                HNF1B                         5.26                            0.65                                3.63 
                         HSD3B1              HSD3B1                      1.37                             1.03                                3.76 
                         HSPB8                 HSPB8                       10.69                            0.55                                2.57 
                         IGF1                     IGF1                            9.35                             0.74                                2.72 
                         IGFBP3                IGFBP3                       8.92                             0.87                                3.79 
                         IL1B                     IL1B                             5.27                             1.175                              5.01 
                         IL6                        IL6                               7.45                             1.72                                7.79 
                         INS                       INS                             1.14                              0.85                                3.35 
                         INSIG2                 INSIG2                       5.85                              0.35                               1.92 
                         INSR                     INSR                          8.97                               0.25                               1.08 
                         ITGB5                   ITGB5                        8.47                               0.34                               1.28 
                         KLK4                     KLK4                          11.26                            0.79                                3.46 
                         LEP                       LEP                             0.96                              0.83                                2.86 
              LEPR                     LEPR                          7.02                              0.43                                1.85 
                         LGALS8                 LGALS8                    7.61                              0.31                                1.38 
                         MAPK1                 MAPK1                    8.49                              0.40                                1.71 
                         MAPKAPK2          MAPKAPK2            7.08                              0.47                                2.93 
                         MC4R                    MC4R                      1.11                               0.97                                3.35 
                         MMP9                   MMP9                    5.04                               1.47                                5.65 
                         MTCH2                  MTCH2                  8.65                                0.23                                1.10 
                         NFKB1                   NFKB1                    6.21                               0.43                                2.55 
                         NPC1                     NPC1                      6.59                                0.17                                0.74 
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                         NPY1R                   NPY1R                   5.50                          0.77                           3.89 
                         NPY5R                   NPY5R                   2.50                          0.85                           3.97 
                         OR2L13                 OR2L13                 2.18                          1.06                            4.18 
                         PAH                       PAH                        3.29                          1.35                            5.97 
                         PCGEM1               PCGEM1                3.72                          1.79                            7.00 
                         PCSK1                   PCSK1                     1.53                          0.96                            3.31 
                         PI3                         PI3                           3.58                         1.28                            5.81 
                         PIK3CB                  PIK3CB                   6.56                          0.39                           1.67 
                         PIK3CA                 PIK3CA                    7.06                         0.27                            1.34 
                         PIK3R1                 PIK3R1                    9.02                          0.40                            1.63 
                         PLA2G2A             PLA2G2A                10.28                       1.33                             6.19 
                         POMC                  POMC                      2.47                         1.07                             4.42 
                         PRKAA2               PRKAA2                  6.84                          0.39                            1.96 
                         PSCA                    PSCA                        7.19                          1.73                            6.87 
                         PSPH                    PSPH                        6.79                          0.55                            3.03 
                         PTEN                    PTEN                        8.95                          0.35                            1.50 
                         RAB6A                 RAB6A                     9.50                          0.19                            0.86 
                         RHOA                   RHOA                      9.59                          0.37                            1.52 
                         SCD                       SCD                         8.86                           0.99                            3.68 
                         SHBG                    SHBG                      2.97                           0.75                            2.69 
                         SIRT1                    SIRT1                      7.08                           0.29                            1.36 
                         SLC2A2                 SLC2A2                   0.84                          0.92                             2.66 
                         SLC2A3                 SLC2A3                   2.54                          0.71                             3.41 
                         SLC2A4                 SLC2A4                   7.01                          0.72                             2.98 
                         SLC39A1               SLC39A1                 8.38                          0.27                             1.15 
                         SLC39A2               SLC39A2                 3.06                          1.29                             5.44 
                         SRD5A2                SRD5A2                   8.26                          0.50                             2.62 
                         STAT1                   STAT1                      9.57                          0.32                             1.28 
                         STAT3                   STAT3                     10.87                         0.29                             1.33 
                         SULT1A1              SULT1A1                 6.55                           0.61                             3.19 
                         TCF7L2                 TCF7L2                     8.59                          0.27                              1.31 
                         TFF1                      TFF1                         4.48                         1.03                               5.16 
                         TGFB1                   TGFB1                     8.60                          0.48                              2.20  
                         TIMP3                   TIMP3                    11.41                         0.48                              2.08 
                         TNF                        TNF                         3.75                           0.93                              4.10 
                         TP53                      TP53                       7.05                           0.45                              2.25 
                         VDR                       VDR                        3.91                           0.67                              3.19 
                         YY1                        YY1                         8.71                           0.22                              1.01 
         
 
                                            
 
                    
        Type          Variable              Label                     Mean                          Std Dev                        Range 
         
        Pin            ACTN2                  ACTN2                   3.57                            2.08                              8.00 
                         ADIPOQ                ADIPOQ                1.51                            0.90                               3.70 
                         ADIPOR1               ADIPOR1              8.84                            0.31                               1.30 
                         ADIPOR2               ADIPOR2              6.54                            0.34                              1.49 
                         AKR1C4                 AKR1C4                1.17                            1.01                               3.42 
                         ALOX12                 ALOX12                2.26                            1.06                               4.32 
                         ALOX15                 ALOX15                2.84                            0.95                               4.13 
                         ALOX15B               ALOX15B             8.81                            1.25                               5.01 
                         ANGPT1                 ANGPT1               7.58                            0.61                              2.40 
                         APOLD1                 APOLD1               7.34                             0.77                              3.07 
                         AR                           AR                         8.67                            0.50                               2.21 
                         BMP2                     BMP2                   4.98                             0.55                               2.83 
                         CGA                        CGA                      2.40                             1.14                               4.59 
                         CRYBB2                 CRYBB2                2.75                             0.87                               3.24 
                         CSNK2A1              CSNK2A1              8.12                             0.29                               1.32 
                         CXCR4                   CXCR4                   8.74                             0.80                               3.62 
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                         CYLD                      CYLD                    7.02                        0.43                               2.16 
                         CYP17A1               CYP17A1             2.51                        1.34                               5.22 
                         CYP19A1               CYP19A1             2.19                        0.97                               4.64 
                         CYP3A4                 CYP3A4               2.09                        1.27                               4.18 
                         EIF2A                     EIF2A                   7.40                        0.53                               2.26 
                         EIF5A                     EIF5A                  10.80                       0.30                               1.09 
                         EPHB2                   EPHB2                 5.12                         0.50                               2.23 
                         ERG                        ERG                     4.90                         1.19                               5.06 
                         ESR1                      ESR1                    7.11                         0.57                               2.51 
                         ESR2                      ESR2                    4.59                         0.95                               4.16 
                         FADS1                   FADS1                 7.00                         0.74                               3.18 
                         FASN                     FASN                   10.45                       0.80                               3.29 
                         FOXO3                  FOXO3                 8.95                        0.30                               1.26 
                         FTO                        FTO                      8.42                        0.23                               0.92 
                         GNPDA2               GNPDA2             6.82                        0.32                                1.36 
                         GOLIM4                GOLIM4              8.23                        0.28                                1.39 
                         GPER1                   GPER1                 5.62                        0.74                                3.07 
                         HLA_DRB3           HLA-DRB3           10.11                      0.69                                2.40 
                         HNF1A                  HNF1A                 2.45                        1.03                                4.15 
                         HNF1B                  HNF1B                  5.63                        0.58                               2.17 
                         HSD3B1                HSD3B1               1.46                        1.21                                4.60 
                         HSPB8                  HSPB8                  10.40                       0.59                               2.32 
                         IGF1                      IGF1                      9.10                        0.72                                3.02 
                         IGFBP3                 IGFBP3                 8.88                        0.80                                3.13 
                         IL1B                      IL1B                       5.26                        1.36                                6.21 
                         IL6                         IL6                         6.98                        1.60                                5.86 
                         INS                        INS                        1.34                        0.98                                3.60 
                         INSIG2                  INSIG2                  5.89                        0.48                                2.20 
                         INSR                      INSR                     9.12                         0.26                               1.19 
                         ITGB5                   ITGB5                   8.54                         0.29                                1.28 
                         KLK4                      KLK4                    11.55                       0.65                                3.01 
                         LEP                         LEP                      1.47                         0.92                                 3.50         
                         LEPR                      LEPR                    6.99                         0.41                                 1.65 
                         LGALS8                 LGALS8                7.64                         0.34                                1.50 
                         MAPK1                 MAPK1                8.52                         0.43                                1.79 
                         MAPKAPK2          MAPKAPK2        7.04                         0.41                                1.89 
                         MC4R                    MC4R                   1.38                        1.24                                 4.00 
                         MMP9                   MMP9                 5.36                        1.47                                 5.59 
                         MTCH2                  MTCH2                8.76                        0.34                                 1.65 
                         NFKB1                   NFKB1                  6.09                        0.51                                 2.04 
                         NPC1                     NPC1                     6.55                        0.21                                 0.96 
                         NPY1R                   NPY1R                  5.54                        0.71                                 2.96 
                         NPY5R                   NPY5R                 2.77                         0.77                                 3.58 
                         OR2L13                 OR2L13                2.45                         0.98                                 3.85 
                         PAH                        PAH                     3.83                         1.42                                  5.99 
                         PCGEM1               PCGEM1              3.94                         1.84                                  6.75 
                         PCSK1                    PCSK1                 1.89                          0.99                                  4.13 
                         PI3                          PI3                       3.70                         1.32                                  5.45 
                         PIK3CB                   PIK3CB                6.71                        0.31                                  1.34 
                         PIK3CA                   PIK3CA                7.01                        0.26                                  0.91 
                         PIK3R1                   PIK3R1                 8.88                       0.36                                   1.42 
                         PLA2G2A               PLA2G2A            11.05                      1.31                                  5.38 
                         POMC                    POMC                  2.50                        0.93                                  3.95 
                         PRKAA2                 PRKAA2              6.93                         0.35                                 1.32 
                         PSCA                      PSCA                    7.68                         2.33                                 9.62 
                         PSPH                      PSPH                    6.84                         0.53                                 2.59 
                         PTEN                      PTEN                    8.95                         0.33                                 1.79 
                         RAB6A                   RAB6A                  9.55                        0.26                                 1.17 
                         RHOA                    RHOA                    9.49                        0.32                                 1.39 
                         SCD                        SCD                       9.13                         0.92                                 3.65 
                         SHBG                     SHBG                    2.79                         0.80                                 2.92 
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                         SIRT1                     SIRT1              7.09                             0.31                                   1.37 
                         SLC2A2                  SLC2A2          1.04                             1.03                                    3.60 
                         SLC2A3               SLC2A3             2.60                             0.72                                    3.24 
                         SLC2A4               SLC2A4             6.86                             0.62                                    2.94 
                         SLC39A1             SLC39A1          8.43                              0.24                                   1.36 
                         SLC39A2             SLC39A2          3.51                             1.86                                    6.44 
                         SRD5A2              SRD5A2           7.99                              0.61                                   2.75 
                         STAT1                 STAT1               9.76                             0.40                                   1.50 
                         STAT3                 STAT3               10.93                           0.34                                   1.46 
                         SULT1A1            SULT1A1           6.69                             0.61                                   2.76 
                         TCF7L2               TCF7L2              8.67                             0.22                                   1.09 
                         TFF1                    TFF1                  4.92                             1.35                                   5.23 
                         TGFB1                 TGFB1              8.47                             0.40                                   1.61 
                         TIMP3                 TIMP3             10.97                            0.47                                   2.01 
                         TNF                      TNF                  3.54                              0.88                                   4.13 
                         TP53                    TP53                7.17                              0.56                                   2.38 
                         VDR                     VDR                  3.90                             0.71                                   2.86 
                         YY1                      YY1                   8.85                             0.27                                   1.18 
         
 
                                             
                     
        Type         Variable            Label                  Mean                          Std Dev                             Range 
        
        Tumor      ACTN2               ACTN2              4.45                              2.66                                   10.65 
                         ADIPOQ             ADIPOQ            1.82                              1.43                                    4.83 
                         ADIPOR1           ADIPOR1           8.85                              0.35                                   1.49 
                         ADIPOR2           ADIPOR2           6.54                              0.37                                   2.01 
                         AKR1C4              AKR1C4            1.77                               1.34                                   4.40 
                         ALOX12              ALOX12            2.51                              1.15                                    5.25 
                         ALOX15              ALOX15            3.23                              1.14                                    4.78 
                         ALOX15B           ALOX15B          8.92                              1.61                                    7.02 
                         ANGPT1             ANGPT1           7.36                               0.77                                    3.34 
                         APOLD1              APOLD1           7.38                               0.66                                   2.76 
                         AR                        AR                     8.75                               0.42                                   1.92 
                         BMP2                  BMP2               4.69                               0.95                                    4.81 
                         CGA                     CGA                  2.41                               1.36                                    5.44 
                         CRYBB2               CRYBB2           3.11                               1.09                                    5.27 
                         CSNK2A1            CSNK2A1        8.12                                0.26                                   1.12 
                         CXCR4                 CXCR4              8.99                               0.88                                    4.46 
                         CYLD                    CYLD                7.06                                0.43                                   2.34   
                         CYP17A1             CYP17A1        3.01                                1.42                                    5.38 
                         CYP19A1             CYP19A1        2.21                                1.20                                    4.88 
                         CYP3A4               CYP3A4           2.30                                1.09                                    4.72 
                         EIF2A                   EIF2A               7.43                                0.52                                    2.72 
                         EIF5A                   EIF5A              10.89                               0.30                                   1.18 
                         EPHB2                 EPHB2              5.42                                0.72                                   2.98 
                         ERG                      ERG                  5.29                                1.53                                   5.90 
                         ESR1                    ESR1                 7.03                                0.66                                   3.46 
                         ESR2                    ESR2                 4.83                                0.95                                   3.61 
                         FADS1                 FADS1              6.69                                0.83                                   3.09 
                         FASN                   FASN                10.57                              0.90                                    4.10 
                         FOXO3                FOXO3              8.92                                0.33                                   1.35 
                         FTO                      FTO                   8.43                                0.31                                   1.47 
                         GNPDA2             GNPDA2          6.98                                 0.50                                   2.66 
                         GOLIM4              GOLIM4           8.35                                 0.32                                   1.19 
                         GPER1                 GPER1              5.47                                 0.79                                   2.95 
                         HLA_DRB3          HLA-DRB3      10.48                                0.81                                   3.31 
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                         HNF1A                 HNF1A            2.47                              1.16                                     5.08 
                         HNF1B                 HNF1B             5.74                              0.78                                    4.34 
                         HSD3B1               HSD3B1          2.15                              1.57                                     6.33 
                         HSPB8                  HSPB8            10.24                             0.89                                    4.37 
                         IGF1                      IGF1                 9.05                             0.82                                    3.59 
                         IGFBP3                 IGFBP3            8.65                              0.96                                    4.24 
                         IL1B                       IL1B                 5.15                             1.16                                     5.56 
                         IL6                         IL6                    6.57                             1.56                                     6.47 
                         INS                        INS                   1.39                             1.20                                     4.40 
                         INSIG2                  INSIG2            5.81                              0.43                                     1.86 
                         INSR                   INSR                  9.03                              0.24                                     1.33 
                         ITGB5                 ITGB5                8.51                              0.33                                     1.58 
                         KLK4                   KLK4                 11.77                             0.83                                     3.67 
                         LEP                      LEP                    1.86                              1.09                                     4.20 
                         LEPR                    LEPR                 6.97                              0.65                                     2.67 
                         LGALS8               LGALS8             7.77                              0.39                                    1.73 
                         MAPK1               MAPK1             8.59                              0.35                                    1.61 
                         MAPKAPK2        MAPKAPK2     7.07                              0.38                                    2.40 
                         MC4R                  MC4R               1.75                              1.28                                     5.40 
                         MMP9                 MMP9             5.59                              1.49                                     6.59 
                         MTCH2                MTCH2            8.83                              0.29                                    1.52 
                         NFKB1                  NFKB1             6.09                              0.65                                    3.50 
                         NPC1                    NPC1               6.55                              0.31                                     1.18 
                         NPY1R                  NPY1R            5.39                              0.88                                     3.23 
                         NPY5R                  NPY5R            2.92                              1.18                                     4.90 
                         OR2L13               OR2L13           2.37                              1.26                                      5.08 
                         PAH                      PAH                 3.83                             1.41                                       5.46 
                         PCGEM1              PCGEM1         4.53                             1.73                                       7.52 
                         PCSK1                   PCSK1            2.30                              1.28                                      5.08 
                         PI3                         PI3                 3.90                              1.22                                       4.65 
                         PIK3CB                  PIK3CB          6.79                              0.47                                      1.86 
                         PIK3CA                  PIK3CA         7.10                               0.28                                     1.19 
                         PIK3R1                  PIK3R1          8.84                               0.50                                     2.14 
                         PLA2G2A              PLA2G2A      10.73                            1.61                                      7.18 
                         POMC                    POMC           2.64                              1.18                                      4.81 
                         PRKAA2                PRKAA2         7.05                             0.40                                      1.77 
                         PSCA                      PSCA             6.53                              1.68                                      7.61 
                         PSPH                      PSPH             6.93                              0.66                                      3.68 
                         PTEN                      PTEN             8.98                              0.29                                      1.44 
                         RAB6A                   RAB6A          9.54                              0.24                                      0.90 
                         RHOA                     RHOA           9.48                              0.32                                      1.29 
                         SCD                         SCD              8.99                              0.96                                      4.72 
                         SHBG                      SHBG           3.08                              1.18                                      5.01 
                         SIRT1                      SIRT1           7.11                               0.32                                     1.69 
                         SLC2A2                   SLC2A2        1.64                              1.39                                      5.08 
                         SLC2A3                   SLC2A3        2.72                              1.11                                      4.51 
                         SLC2A4                   SLC2A4        6.76                              0.79                                      3.47 
                         SLC39A1                 SLC39A1      8.44                              0.32                                     1.78 
                         SLC39A2                 SLC39A2      2.94                              1.33                                     5.63 
                         SRD5A2                  SRD5A2        7.91                             0.71                                     2.90 
                         STAT1                     STAT1          9.85                              0.47                                     1.65 
                         STAT3                     STAT3         10.91                             0.38                                     1.60 
                         SULT1A1                SULT1A1      6.95                              0.70                                     3.46 
                         TCF7L2                   TCF7L2         8.66                              0.27                                      1.51 
                         TFF1                        TFF1             4.15                              1.01                                      4.43 
                         TGFB1                     TGFB1          8.50                              0.53                                     1.93 
                         TIMP3                     TIMP3         10.83                             0.55                                     2.33 
                         TNF                         TNF              3.94                               1.34                                      6.44 
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                         TP53                       TP53            7.31                               0.47                                      2.13 
                         VDR                         VDR            4.04                                0.67                                     3.28 
                         YY1                          YY1              8.86                               0.23                                     0.86 
 
 
 
 
 
 
 
